Treatment of dementia in community-dwelling and institutionalized Medicare beneficiaries [corrected] [published erratum appears in J AM GERIATR SOC 2007 Oct;55(10):1697.
In: Journal of the American Geriatrics Society, Jg. 55 (2007-10-01), Heft 10, S. 1508-1516
Online
academicJournal
Zugriff:
OBJECTIVES: To establish nationally representative estimates of the use of agents to treat Alzheimer's disease and related dementias (ADRDs) and related behavioral symptoms in Medicare beneficiaries and to describe medication use according to residential status and other patient characteristics. DESIGN: Cross-sectional prevalence study. SETTING: Community and various long-term care (LTC) settings. PARTICIPANTS: Twelve thousand six hundred ninety-seven beneficiaries from the 2002 Medicare Current Beneficiary Survey (MCBS), of whom 11,593 were community dwelling and 1,104 resided in various LTC settings. MEASUREMENTS: ADRDs were identified according to International Classification of Diseases, Ninth Revision, codes in Medicare claims and self- and proxy reports. Medication use was derived from self-reports (community) and extracts of facility medication administration records (LTC). RESULTS: In 2002, an estimated 3.4 million Medicare beneficiaries were diagnosed with ADRDs (8.1%), of whom 58.9% resided in the community (prevalence rate=5.1%) and 41.1% resided in LTC facilities (prevalence rate=57.2%). Use of antidementia drugs was similar across settings, with 24.7% of subjects with dementia in the community and 26.3% of those in LTC receiving prescriptions for donepezil, galantamine, or rivastigmine. Use of haloperidol was comparable (and low) in both settings. Use of atypical antipsychotics, especially risperidone, olanzapine, and quetiapine, was much higher in LTC residents (21.0%, 11.9%, and 7.1%, respectively) than in the community (5.1%, 4.0%, and 2.3%). CONCLUSION: The prevalence of ADRDs in LTC settings is much larger than in the community, but there is little difference in the proportions receiving antidementia drugs, although LTC residents are more likely to be treated with atypical antipsychotics (risperidone, olanzapine, and quetiapine), presumably for behavioral symptoms. [ABSTRACT FROM AUTHOR]
Copyright of Journal of the American Geriatrics Society is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Treatment of dementia in community-dwelling and institutionalized Medicare beneficiaries [corrected] [published erratum appears in J AM GERIATR SOC 2007 Oct;55(10):1697.
|
---|---|
Autor/in / Beteiligte Person: | Gruber-Baldini, AL ; Stuart, B ; Zuckerman, IH ; Simoni-Wastila, L ; Miller, R |
Link: | |
Zeitschrift: | Journal of the American Geriatrics Society, Jg. 55 (2007-10-01), Heft 10, S. 1508-1516 |
Veröffentlichung: | 2007 |
Medientyp: | academicJournal |
ISSN: | 0002-8614 (print) |
DOI: | 10.1111/j.1532-5415.2007.01387.x |
Sonstiges: |
|